Modulating trained immunity has therapeutic potential in a broad range of diseases, including infectious diseases, autoinflammatory disorders, cancer, atherosclerosis, and organ transplantations.5–7,9 Our data show that acid ceramidase, and ceramide metabolism, represent promising therapeutic targets that can be explored to control trained immunity. This evidence concerns the gene ASAH1 and cancer.